Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Sankalp Sethi and Jeffrey Vacirca, MD, FACP, examine partnering with pharma during COVID-19

Sankalp Sethi, of ZS, and Jeffrey Vacirca, of New York Cancer & Blood Specialists, examine community cancer care during COVID-19 and partnering with pharma

Tags: Current State of Community Oncology PracticesPatient Care (includes Supportive Care, Palliative Care, Survivorship, QOL, Advocacy, Adverse Events, Pain Management)

Published: 04 June 2020

Recent Videos: Policy and Value (includes Cost, Quality, Reimbursement, Guidelines, Pathways, Insurance)

video

Sankalp Sethi & Jeffrey Patton, MD, on how pharma can help community oncology’s COVID-19 challenges

Sankalp Sethi, of ZS, and Jeffrey Patton, CEO of OneOncology, discuss how pharma can help community oncology’s challenges associated with ...

video

Sankalp Sethi and Jeffrey Vacirca, MD, FACP, examine partnering with pharma during COVID-19

Sankalp Sethi, of ZS, and Jeffrey Vacirca, of New York Cancer & Blood Specialists, examine community cancer care during COVID-19 ...

video

Dinesh Kapur, MD, explains why his practice eventually decided to join OneOncology

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, explains why Eastern Connecticut Hematology & Oncology eventually decided to give up ...

video

Dinesh Kapur, MD, describes how OneOncology welcomed his group and impressive treatment resources

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, describes how OneOncology has welcomed his group and impressive cancer treatment resources

video

Dinesh Kapur, MD, provides thoughts on early impressions of CMMI and the Oncology Care First model

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, provides thoughts on early impressions of CMMI and the Oncology Care First ...

video

Dinesh Kapur, MD, shares thoughts on OCM reducing the cost of care and status of the quality

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, expresses thoughts on OCM reducing the cost of care and describes whether ...

video

Robert J. Brooks, MD, offers advantages and disadvantages of joining a large oncology group

Dr. Brooks, Medical Oncologist/Hematologist, Arizona Blood and Cancer Specialists, offers advantages and disadvantages of joining a large oncology group

video

Robert J. Brooks, MD, advises oncology practices that are considering whether to stay independent or to join a larger group of oncologists

Dr. Brooks, Medical Oncologist/Hematologist, Arizona Blood and Cancer Specialists, advises oncology practices that are considering whether to stay independent or ...

video

Stephen M. Schleicher, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, provides examples of how aligning incentives has improved the quality of cancer care delivery ...

video

Sibel Blau, MD, expounds upon maintaining quality care with non-clinical staff working remotely

Dr. Blau, Chief Operations Officer, Northwest Medical Specialties, expounds upon maintaining quality care with non-clinical staff working remotely and steps ...

Related Videos

video-image

Sankalp Sethi & Jeffrey Patton, MD, on how pharma can help community oncology’s COVID-19 challenges

video-image

Dinesh Kapur, MD, explains why his practice eventually decided to join OneOncology

video-image

Dinesh Kapur, MD, describes how OneOncology welcomed his group and impressive treatment resources

video-image

Dinesh Kapur, MD, provides thoughts on early impressions of CMMI and the Oncology Care First model

video-image

Dinesh Kapur, MD, shares thoughts on OCM reducing the cost of care and status of the quality

video-image

Robert J. Brooks, MD, offers advantages and disadvantages of joining a large oncology group

video-image

Robert J. Brooks, MD, advises oncology practices that are considering whether to stay independent or to join a larger group of oncologists

video-image

Stephen M. Schleicher, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Stephen M. Schleicher, MD, MBA, describes how the cost of drugs are impacting the effectiveness of APMs

video-image

Sibel Blau, MD, expounds upon maintaining quality care with non-clinical staff working remotely

video-image

Debra Patt, MD, on how applied informatics is being incorporated into cancer patient management

video-image

Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

video-image

Jeffrey Patton, MD, expounds upon maintaining quality care with non-clinical staff working remotely

video-image

Jeffrey Patton, MD, anticipates whether smaller practices will be able to survive the pandemic or if they are in danger of closing due to lack of resources

video-image

Jeffrey Patton, MD, describes his care team's strengths during this pandemic and habits to continue post pandemic

video-image

Jeffrey Patton, MD, provides thoughts regarding the future of cancer care amidst a national crisis and providing quality cancer care across the country

video-image

Alti Rahman, MHA, MBA, explains the adoption of telemedicine and reimbursement expectations

video-image

Bo Gamble, expands on the practice coding problem and repercussions of improper coding

video-image

Bo Gamble, recommends best practices regarding proper coding for oncology practices

video-image

Bo Gamble, illustrates how practices are dealing with adding new CMS telehealth/telemedicine in the midst of the COVID-19 pandemic

video-image

Bo Gamble, shares concerns on the coding changes coming in 2021 and the impact impact they may have on community oncology

video-image

Antonio Ciaccia, expresses advantages Pharmacy Benefit Managers may bring to the healthcare system

video-image

Antonio Ciaccia, demonstrates how Pharmacy Benefit Managers are gaming the healthcare system

video-image

Antonio Ciaccia, explains how smaller pharmacies compete with PBMs and how they are being priced out

video-image

Antonio Ciaccia, on changes that need to be made on a national level that would bring Pharmacy Benefit Managers (PBMs) more in line with the interests of cancer patients and payers

video-image

Kashyap Patel, MD, recalls his practice's adaption to OCM 1.0 and further adaption to OCM 2.0

video-image

Kashyap Patel, MD, updates us on the stance of OCM 2.0 as of the annual COA meeting 2020

video-image

Kashyap Patel, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Kashyap Patel, MD, expresses early impressions of CMMI and the Oncology Care First (OCF) model

video-image

Thomas Sonderberg, expresses opinion on components of care that are essential for employers to consider as part of their comprehensive coverage of their employees

video-image

Thomas Sonderberg, on the needs of small to midsize employers compared to larger employers with more contract leverage

video-image

Thomas Sonderberg, provides concerns of an employer coverage of cancer care and also the good news in cancer care

video-image

Thomas Sonderberg, describes the scope of cancer care cost to an employer and variations in coverage by types of employer

video-image

Stephen M. Schleicher, MD, MBA, on early impressions of CMMI and the Oncology Care First (OCF) model

video-image

Sibel Blau, MD, describes her care team's strength while embracing new communications and technology in the midst of the COVID-19 pandemic

video-image

Steven D'Amato, RPh, BScPharm, on maintaining quality of care with non-clinical staff working remotely and the steps being taken to support this situation

video-image

Thomas Sonderberg, describes challenges that employers face managing cancer care costs and the price of drugs

video-image

Alti Rahman, MHA, MBA, shares examples of new practices being implemented to safely treat cancer patients through the COVID-19 pandemic

video-image

Martin Dietrich, MD, PhD, provides examples of how genetic profile tests are being used to make decisions on patient care

video-image

Kashyap Patel, MD, describes whether quality of care has suffered or improved as OCM reduces the cost of cancer care

video-image

Kashyap Patel, MD, regarding two-sided risk and participation in the OCM

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Russell Gollard, MD, offers opinion on why IDNs are a cancer delivery model of the future

video-image

Russell Gollard, MD, considers the difference between a hospital and a non-hospital IDN

video-image

Russell Gollard, MD, considers the main impediments to coordinated care

video-image

Russell Gollard, MD, explains how IDNs effectively coordinate cancer care

video-image

Andrew Hertler, MD, FACP, on measuring success in value-based cancer care delivery

video-image

Andrew Hertler, MD, FACP, offers advice to oncology practices entering the value-based world

video-image

Andrew Hertler, MD, FACP, considers the benefits of participating in an ACO

video-image

Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements

video-image

Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Jennie Crews, MD, MMM, FACP, on the influence of MIPS & MACRA at Seattle Cancer Care Alliance

video-image

Satish Shah, MD, on how technology can ease the burden of reporting quality measures

video-image

Kavita Patel, MD, MS, FACP, discusses how 340B has impacted her practice

video-image

Kavita Patel, MD, MS, FACP, regarding the impact of MACRA on payment reform

video-image

Stephen Grubbs, MD, considers how MIPS & MACRA are transforming the delivery of cancer care

video-image

Stephen Grubbs, MD, describes the tools ASCO provides to help practices move toward value-based care

video-image

Stephen Grubbs, MD, on what ASCO is doing to help educate members about MIPS & MACRA

video-image

Bobby Green, MD, analyzes the role of health technology companies in the design of APMs

video-image

Ann Marie Edwards on how patients have been impacted by value-based care

video-image

Ann Marie Edwards tells us how technology has impacted the delivery of value-based care

video-image

Ann Marie Edwards examines how 340B has impacted Alliance Cancer Specialists

video-image

Ann Marie Edwards considers the physician practice models poised to succeed in a value-based world

video-image

George Daneker, MD, on the role of CMS and commercial payers in delivering value-based care

video-image

George Daneker, MD, regarding the role of consistency in the delivery of high-quality care

video-image

Jennie Crews, MD, MMM, FACP, on embracing new value-based oncology models

video-image

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

video-image

Sibel Blau, MD, discusses how 340B has impacted Northwest Medical Specialties

video-image

Sibel Blau, MD, shares how her practice has transformed in order to participate in MACRA

video-image

Roy Beveridge, MD, regarding the most cost-efficient alternative payment models

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

video-image

Charles Saunders, MD, considers EHR providers in an era of value-based care

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

video-image

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

video-image

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

video-image

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

video-image

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

video-image

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

video-image

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

video-image

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

video-image

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

video-image

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

video-image

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

video-image

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

video-image

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

video-image

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

video-image

Ed Bassin, Ph.D., on if there will be health care savings with the implementation of the OCM

video-image

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

video-image

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

video-image

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

video-image

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

video-image

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

video-image

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

video-image

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

video-image

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

video-image

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

video-image

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

video-image

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

video-image

Linda Bosserman, MD, explains what MACRA means for oncologists today

video-image

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

video-image

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

video-image

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

video-image

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

video-image

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

video-image

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

video-image

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

video-image

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

video-image

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

video-image

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, discusses the practicality of the value tool at Dayton Physicians Network

video-image

Perspective on the NCCN Evidence Blocks by Charles Bane, MD

video-image

Perspective on the ASCO Value Framework by Charles Bane, MD

video-image

Bruce Gould, MD, explains how the value tools could be used in the community practice setting

video-image

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD

video-image

Perspective on the ASCO Value Framework provided by Bruce Gould, MD

video-image

Bruce Gould, MD, explains ASCO’s policy toward clinical pathways at this time

video-image

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

video-image

Bruce Gould, MD, describes the concerns his practice has with clinical pathways

video-image

Barbara McAneny, MD, explains why CMS implemented the ASP experiment

video-image

Barbara McAneny, MD, informs as to what practices should know about MACRA

video-image

Barbara McAneny, MD, reviews the COME HOME project’s influence on the Oncology Care Model

video-image

Barbara McAneny, MD, discusses COME HOME’s adaptability to other community oncology practices

video-image

Barbara McAneny, MD, talks about the COME HOME project’s impact on community oncology practices

video-image

Barbara McAneny, MD, discusses the COME HOME project’s future

video-image

Jeff Patton, MD, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

video-image

Jeff Patton, MD, explains how Tennessee Oncology benefits from being a member of COA

video-image

Jeff Patton, MD, explains why the 2016 COA meeting is a must attend meeting

video-image

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

video-image

Deborah Patt, MD, shares her concerns about the CMS ASP Experiment and Part B reimbursement

video-image

Deborah Patt, MD, tells us how chemotherapy costs figure into total care

video-image

Deborah Patt, MD, points out how oncologists can reduce cancer costs

video-image

Deborah Patt, MD, details surprising outcomes from a recent cost study

video-image

Deborah Patt, MD, looks at the bigger expense drivers in cancer care

video-image

David Eagle, MD, gives his opinion on the CMS ASP Experiment

video-image

David Eagle, MD, enumerates what oncologists can do to bring cancer costs down

video-image

David Eagle, MD, lists outcomes from the COA study surprising to oncologists

video-image

David Eagle, MD, details the bigger expenses driving up cancer care costs based on the COA study

video-image

David Eagle, MD, compares costs for treating cancer vs. non-cancer based on the COA study

video-image

David Eagle, MD, talks about COA’s Cost Drivers of Cancer Care study

video-image

Bhuvana Sagar, MD, tells us about the Cigna medical home for oncologists

video-image

Bhuvana Sagar, MD, discusses Cigna’s work with oncologists to find alternative payment models

video-image

Bhuvana Sagar, MD, explains the need for alternative payment models in oncology

video-image

Barry Russo explains the impact of the CMS ASP Experiment

video-image

Practices need to get ready to replace buy and bill explains Barry Russo

video-image

Bruce Gould, MD, explains the characteristics that makes a practice ready for OCM

video-image

Brad Prechtl briefs us on his concerns with the“Medicare Experiment” and its impact

video-image

Brad Prechtl tells how his practice is working to improve cancer care

video-image

Brad Prechtl talks about how community oncology practices can survive today

video-image

Brad Prechtl explains the benefits of community oncology practices joining forces

video-image

Bhuvana Sagar, MD, forecasts the possible Cigna adoption of a Medicare OCM model

video-image

Participation in the Oncology Care Model (OCM) as explained by Barry Russo

video-image

Barry Russo explains how important it is to embrace alternative payment models

video-image

Barry Russo tells us how his practice is getting ready for value-based care

video-image

Patrick Cobb, MD, FACP, looks ahead to treatment innovations that will make a difference

video-image

Patrick Cobb, MD, FACP, talks about some exciting, recent innovations in cancer treatment

video-image

Michael Diaz, MD, talks about working with payers to add quality and value

video-image

Michael Diaz, MD, discusses the challenges in adopting quality and value measures

video-image

Michael Diaz, MD, talks about why the community oncology setting is the best value for patients

video-image

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

video-image

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

video-image

John Fox, MD, talks about the new value tools from ASCO and NCCN

video-image

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

video-image

A look at cancer clinical pathways with Charles Bane, MD

video-image

Ricky Newton, CPA, updates us on COPA

video-image

Ricky Newton, CPA, details how COPA’s website helps practice managers, pharmacists, and patients

video-image

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

video-image

Ricky Newton, CPA, tells us what follow up to expect from COPA’s new brief

video-image

Robert Baird fills us in on the Value-Based Purchasing Modifier's impact on Dayton

video-image

Robert Baird details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

video-image

Robert Baird explains how Dayton physicians and payers are collaborating on APMs

video-image

Robert Baird answers questions on Dayton’s participation in the Oncology Care Model

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Skip Burris, MD, looks at the promise of immunotherapies in combination

video-image

Skip Burris, MD, explains goals and outcomes of the My Pathway trial

video-image

Skip Burris, MD, reflects on the promise and concerns with liquid biopsies

video-image

Ted Okon tells us why the CNS ASP Experiment is a bad idea

video-image

Embrace alternative payment models explains Ted Okon

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, explains the role an in-house pharmacy plays in the quality equation

video-image

Sue Naeyaert predicts whether we will see more cancer biosimilars soon

video-image

Sue Naeyaert tells us what to expect in pricing biosimilars

video-image

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert

video-image

Sue Naeyaert explains the proposed reimbursement of biosimilars by CMS

video-image

Skip Burris, MD, discusses how precision medicine is changing cancer treatment

video-image

Sue Naeyaert provides her vision of the biosimilar products in development

video-image

Todd Murphree briefs us on ACHC’s oncology accreditation process

video-image

Todd Murphree, PharmD, discusses how ACHC accreditation benefits his practice

video-image

Ted Okon discusses the sessions that stand out at this year's annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon provides an overview of the Cost Drivers in Cancer Care study

video-image

Mary Kruczynski speaks to those who were unable to attend the 2016 Annual COA meeting

video-image

Mary Kruczynski tells us how the 2016 Annual COA meeting benefits health care providers

video-image

Mary Kruczynski reflects on highlights from COA

video-image

Lucio Gordan, MD, lists takeaways from COA that can benefit his own practice

video-image

Lucio Gordan, MD, debriefs providers who didn’t attend on highlights from COA

video-image

Lucio Gordan, MD, reflects on key messages from this year’s COA

video-image

Jeff Vacirca, MD, explains the relevance of the COA/Milliman study to his practice

video-image

Jeff Vacirca, MD, talks about what his community oncology practice is doing to survive

video-image

Jeff Patton, MD, explains how his practice is working to develop alternative payment models

video-image

COA is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD

video-image

Robert Baird tells us what MIPS are and how practices might use them

video-image

Patrick Cobb, MD, discusses treatment innovations and managing patient’s expectations

video-image

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

video-image

David Eagle, MD, compares treatment costs in different settings

video-image

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed

video-image

Michael Kolodziej, MD, describes the breadth and depth of alternative payment models

video-image

Michael Kolodziej, MD, tells us why alternative payment models are needed

video-image

Kavita Patel, MD, MS, explains how 340B is impacting cancer care

video-image

Kavite Patel, MD, MS, tells us whether ACOs are having an impact on oncologists

video-image

Michael Kolodziej, MD, discusses alternative payment models of the future

video-image

John Iacuone, MD, MBA, explains how practices stay independent in pay for performance environment

video-image

Bobby Green, MD, MSCE, explains the frustrations with data coming from oncology practices

video-image

Kavita Patel, MD, MS discusses how important cancer care management is to Medicare

video-image

William Harwin, MD, gives his opinion if practices can survive in today's value based environment

video-image

John Sprandio, MD, explains how his practice worked with CMS to help develop the Oncology Care Model

video-image

Harold Miller discusses the barriers in the fee for service model

video-image

Derek Raghavan, MD, examines the projected cost of new GNRH antagonist therapy and its implications

video-image

Marcia Brose, MD, PhD, provides opinion on who should be tested TRK fusions

video-image

Marcia Brose, MD, PhD, expounds on what should be done for patients who progress on larotrectinib

video-image

Marcia Brose, MD, PhD, on biopsy requirements for optimal evaluation for actionable TRK fusions

video-image

Marcia Brose, MD, PhD, describes how testing for TRK abnormalities are accomplished

video-image

Marcia Brose, MD, PhD, discusses the dosing, safety and efficacy of larotrectinib reported at ASCO20

video-image

Marcia Brose, MD, PhD, provides an overview of TRK fusion treatment in cancer patients

video-image

Daneng Li, MD, on the study results investigating the geriatric assessment tool & chemo side effects

video-image

Daneng Li, MD, describes the geriatric assessment tool developed at City of Hope

video-image

Bruce Feinberg DO, explains strategies that are or should be provided for managing cancer survivors

video-image

Bruce Feinberg, DO, provides examples of social determinants of health and how they qualify as this

video-image

Bruce Feinberg, DO, discusses the importance of social determinants to the health of cancer patients' outcomes

video-image

Bruce Feinberg, DO, on the understanding medical oncologists have on social determinants of health

video-image

Robert J. Brooks, MD, describes how OneOncology has welcomed his group and impressive resources that help treat cancer patients

video-image

Sibel Blau, MD, shares examples of applied informatics being incorporated into patient management

video-image

Sibel Blau, MD, on the improvement of care via AI, especially in high risk cancer patients

video-image

Kathy Oubre, details how creating tailored patient education has enhanced patient/provider relationships

video-image

Kathy Oubre, considers the predicted surge in cancer patients after the COVID-19 pandemic

video-image

Kathy Oubre, offers best practices and new programs being implemented to safely treat patients during the COVID-19 pandemic

video-image

Steven D'Amato, RPH, BSPharm, on his team's strength as a result of the pandemic and habits to continue

video-image

Kathy Oubre, on cancer patients being given home infusions of treatments during the COVID-19 pandemic

video-image

Jeffrey Patton, MD, elaborates on critical success factors for providing quality cancer care during the COVID-19 pandemic

video-image

Debra Patt, MD, on how informatics work with physicians to aid in treatment decision making at the point of care

video-image

Charles Loprinzi, MD, on the importance of physician communication in making an end of life plan

video-image

Charles Loprinzi, MD, considers the best approach to preventing nausea during chemotherapy

video-image

Charles Loprinzi, MD, discusses managing nasal vestibulitis during cancer treatment

video-image

Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology

video-image

Erin Stevens, MD, on how treating sexual dysfunction fits into a symptom management plan

video-image

Erin Stevens, MD, elaborates on interventions to address sexual dysfunction in cancer patients

video-image

Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

video-image

Erin Stevens, MD, considers the prevalence of sexual dysfunction in advanced cancer patients

video-image

Sandip Patel, MD, discusses some solutions for managing toxicities associated with immunotherapies

video-image

Sandip Patel, MD, considers immunotherapy combinations and the likelihood of severe adverse events

video-image

Sandip Patel, MD, on identifying patient types likely to experience immune-related adverse events

video-image

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapies

video-image

Sandip Patel, MD, on the role of immunotherapies when treating cancer near end of life

video-image

Sharon Bober, PhD, describes how treating sexual dysfunction fits into a symptom management plan

video-image

Sharon Bober, PhD, considers intervention methods to address sexual dysfunction in cancer patients

video-image

Sharon Bober, PhD, explains how sexual health fits into quality of life in patient-reported outcomes

video-image

Sharon Bober, PhD, elaborates on the prevalence of sexual dysfunction in advanced cancer patients

video-image

Timothy Morgenthaler, MD, on what drugs seem to be most effective when treating insomnia

video-image

Timothy Morgenthaler, MD, discusses prevention of insomnia in susceptible advanced cancer patients

video-image

Timothy Morgenthaler, MD, regarding the prevalence of insomnia when treating advanced cancer

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on the role of a medical home and palliative care

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on how palliative care looks in a rural practice setting

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on innovations that support the integration of palliative care

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, discusses integrating palliative care in cancer centers

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on incorporating palliative care at Billings Cancer Center

video-image

Rudolph Navari, MD, considers how treating nausea fits into a broader symptom management plan

video-image

Rudolph Navari, MD, regarding effective drugs or drug regimens when treating CINV in advanced cancer

video-image

Rudolph Navari, MD, on identifying advanced cancer patients more likely to experience severe nausea

video-image

Rudolph Navari, MD, describes the prevalence of nausea when treating advanced cancer

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference

video-image

Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network

video-image

Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients

video-image

Skip Burris, MD, offers his opinion on molecular profiling patients

video-image

William Harwin, MD, describes the shift from fee for service to value-based care

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

video-image

Managing patients on regorafenib including adverse events